Skip to main content


Front. Pharmacol.
Sec. Renal Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1360997

Effects and safety of Ophiocordyceps Sinensis Preparation in the Adjuvant Treatment for Dialysis Patients: a Systematic Review and Meta-analysis

Provisionally accepted
Meixi Liu Meixi Liu 1*Chengji Cui Chengji Cui 1Tianying Chang Tianying Chang 1Yingzi Cui Yingzi Cui 1Qingshan Zhou Qingshan Zhou 1Shoulin Zhang Shoulin Zhang 1Xing Liao Xing Liao 2
  • 1 The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin Province, China
  • 2 Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Science, Dongcheng, China

The final, formatted version of the article will be published soon.

    Ethnopharmacological relevance: Ophiocordyceps sinensis (O. sinensis), a genus of ascomycete fungi, has been widedly used in China as a dietary supplement or natural remedy and intensively studied in various disease models with its immunomodulatory potentials.It is a rich source of various bioactive compounds and used for treating end-stage renal disease. This systematic review with clinical evidence aimed to highlight the efficacy and safety of O.Sinensis as an adjuvant treatment for patients undergoing dialysis.A systematic search through nine electronic databases up to April 31, 2024, was conducted for related studies. The Cochrane risk-of-bias tool was used to evaluate the quality of studies. The Grading of Recommendations Assessment, Development, and Evaluation system was used to assess the certainty of evidence. Two researchers independently searched the literature and evaluated the risk of bias.Results: After the screening, 35 randomized controlled trials (RCTs) involving 2914 patients were eventually included. The meta-analysis showed that using O. sinensis effectively reduced the following outcomes in patients undergoing dialysis: C-reactive protein (15RCTs, MD = -2.22, , 95% CI -3.24 to -1.20; very low certainty evidence); creatinine (22RCTs, MD =1.33, 95% CI -1.79 to -0.87 ; very low certainty evidence); blood urea nitrogen (21RCTs, MD =-1.57, 95% CI -2.07 to -1.07 ; low certainty evidence);. It could also effectively improve the following outcomes in patients undergoing dialysis: albumin (20RCTs, MD =-0.81, 95% CI -1.21 to -0.41; low certainty evidence); hemoglobin (19RCTs, MD =-1.00, 95% CI -1.43 to -0.57; low certainty

    Keywords: Dialysis, End-stage renal disease (ESRD), Meta-analysis, Ophiocordyceps sinensispreparation, randomized controlled trials, Systematic review

    Received: 24 Dec 2023; Accepted: 11 Jun 2024.

    Copyright: © 2024 Liu, Cui, Chang, Cui, Zhou, Zhang and Liao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Meixi Liu, The Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, 130021, Jilin Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.